{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T01:33:03Z","timestamp":1780968783146,"version":"3.54.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,2,21]],"date-time":"2023-02-21T00:00:00Z","timestamp":1676937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,2,21]],"date-time":"2023-02-21T00:00:00Z","timestamp":1676937600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiol Ther"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s40119-023-00304-x","type":"journal-article","created":{"date-parts":[[2023,2,21]],"date-time":"2023-02-21T21:29:26Z","timestamp":1677014966000},"page":"341-359","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Efficacy and Safety of Evolocumab in Chinese Patients with Primary Hypercholesterolemia and Mixed Dyslipidemia: 12-Week Primary Results of the HUA TUO \u534e\u4f57 Randomized Clinical Trial"],"prefix":"10.1007","volume":"12","author":[{"given":"Hong","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weimin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhouqing","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajun","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuecheng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongye","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaochun","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Laura","family":"Monsalvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"You","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jackie","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lily","family":"Xin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiyan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"HUA TUO study investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,21]]},"reference":[{"issue":"25","key":"304_CR1","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","volume":"76","author":"GA Roth","year":"2020","unstructured":"Roth GA, Mensah GA, Johnson CO, et al. Global burden of cardiovascular diseases and risk factors, 1990\u20132019: update from the GBD 2019 study. J Am Coll Cardiol. 2020;76(25):2982\u20133021.","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"304_CR2","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1056\/NEJMsa050467","volume":"353","author":"J He","year":"2005","unstructured":"He J, Gu D, Wu X, et al. Major causes of death among men and women in China. N Engl J Med. 2005;353(11):1124\u201334.","journal-title":"N Engl J Med"},{"issue":"1","key":"304_CR3","first-page":"1","volume":"14","author":"WW Chen","year":"2017","unstructured":"Chen WW, Gao RL, Liu LS, et al. China cardiovascular diseases report 2015: a summary. J Geriatr Cardiol. 2017;14(1):1\u201310.","journal-title":"J Geriatr Cardiol"},{"issue":"1","key":"304_CR4","first-page":"1","volume":"17","author":"LY Ma","year":"2020","unstructured":"Ma LY, Chen WW, Gao RL, et al. China cardiovascular diseases report 2018: an updated summary. J Geriatr Cardiol. 2020;17(1):1\u20138.","journal-title":"J Geriatr Cardiol"},{"issue":"2","key":"304_CR5","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1139\/O07-004","volume":"85","author":"L Liu","year":"2007","unstructured":"Liu L. Cardiovascular diseases in China. Biochem Cell Biol. 2007;85(2):157\u201363.","journal-title":"Biochem Cell Biol"},{"key":"304_CR6","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.atherosclerosis.2016.02.006","volume":"248","author":"L Pan","year":"2016","unstructured":"Pan L, Yang Z, Wu Y, et al. The prevalence, awareness, treatment and control of dyslipidemia among adults in China. Atherosclerosis. 2016;248:2\u20139.","journal-title":"Atherosclerosis"},{"key":"304_CR7","unstructured":"Joint Committee for Guideline Revision National Expert Committee on Cardiovascular Diseases. 2016 Chinese guidelines for the management of dyslipidemia in adults. J Geriatr Cardiol. 2018;15(1):1\u201329."},{"issue":"1","key":"304_CR8","first-page":"71","volume":"36","author":"W Ding","year":"2015","unstructured":"Ding W, Dong H, Mi J. Prevalence of dyslipidemia in Chinese children and adolescents: a meta-analysis. Zhonghua Liu Xing Bing Xue Za Zhi. 2015;36(1):71\u20137.","journal-title":"Zhonghua Liu Xing Bing Xue Za Zhi"},{"issue":"12","key":"304_CR9","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1001\/jama.2016.13985","volume":"316","author":"MG Silverman","year":"2016","unstructured":"Silverman MG, Ference BA, Im K, et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA. 2016;316(12):1289\u201397.","journal-title":"JAMA"},{"issue":"1","key":"304_CR10","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, et al. 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111\u201388.","journal-title":"Eur Heart J"},{"issue":"25","key":"304_CR11","first-page":"e1082","volume":"139","author":"SM Grundy","year":"2019","unstructured":"Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082\u2013143.","journal-title":"Circulation"},{"issue":"2","key":"304_CR12","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.atherosclerosis.2014.05.916","volume":"235","author":"S Zhao","year":"2014","unstructured":"Zhao S, Wang Y, Mu Y, et al. Prevalence of dyslipidaemia in patients treated with lipid-lowering agents in China: results of the DYSlipidemia International Study (DYSIS). Atherosclerosis. 2014;235(2):463\u20139.","journal-title":"Atherosclerosis"},{"issue":"4","key":"304_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0047681","volume":"8","author":"F Gao","year":"2013","unstructured":"Gao F, Zhou YJ, Hu DY, et al. Contemporary management and attainment of cholesterol targets for patients with dyslipidemia in China. PLoS One. 2013;8(4):e47681.","journal-title":"PLoS ONE"},{"issue":"1","key":"304_CR14","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/jcph.766","volume":"57","author":"MK Ito","year":"2017","unstructured":"Ito MK, Santos RD. PCSK9 inhibition with monoclonal antibodies: modern management of hypercholesterolemia. J Clin Pharmacol. 2017;57(1):7\u201332.","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"304_CR15","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1111\/dom.13680","volume":"21","author":"AJ Lorenzatti","year":"2019","unstructured":"Lorenzatti AJ, Eliaschewitz FG, Chen Y, et al. Randomised study of evolocumab in patients with type\u00a02 diabetes and dyslipidaemia on background statin: primary results of the BERSON clinical trial. Diabetes Obes Metab. 2019;21(6):1455\u201363.","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"304_CR16","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1111\/dom.13700","volume":"21","author":"Y Chen","year":"2019","unstructured":"Chen Y, Yuan Z, Lu J, et al. Randomized study of evolocumab in patients with type\u00a02 diabetes and dyslipidaemia on background statin: pre-specified analysis of the Chinese population from the BERSON clinical trial. Diabetes Obes Metab. 2019;21(6):1464\u201373.","journal-title":"Diabetes Obes Metab"},{"key":"304_CR17","unstructured":"Joint committee issued Chinese guideline for the management of dyslipidemia in adults. [2016 Chinese guideline for the management of dyslipidemia in adults]. Zhonghua Xin Xue Guan Bing Za Zhi. 2016;44(10):833\u201353."},{"issue":"18","key":"304_CR18","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1001\/jama.2014.4030","volume":"311","author":"JG Robinson","year":"2014","unstructured":"Robinson JG, Nedergaard BS, Rogers WJ, et al. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. JAMA. 2014;311(18):1870\u201382.","journal-title":"JAMA"},{"issue":"7","key":"304_CR19","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/s40262-017-0620-7","volume":"57","author":"S Kasichayanula","year":"2018","unstructured":"Kasichayanula S, Grover A, Emery MG, et al. Clinical pharmacokinetics and pharmacodynamics of evolocumab, a PCSK9 inhibitor. Clin Pharmacokinet. 2018;57(7):769\u201379.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"304_CR20","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.amjcard.2015.10.021","volume":"117","author":"A Kiyosue","year":"2016","unstructured":"Kiyosue A, Honarpour N, Kurtz C, Xue A, Wasserman SM, Hirayama A. A phase\u00a03 study of evolocumab (AMG 145) in statin-treated Japanese patients at high cardiovascular risk. Am J Cardiol. 2016;117(1):40\u20137.","journal-title":"Am J Cardiol"},{"issue":"1","key":"304_CR21","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.016839","volume":"10","author":"ML Daviglus","year":"2021","unstructured":"Daviglus ML, Ferdinand KC, Lopez JAG, Wu Y, Monsalvo ML, Rodriguez CJ. Effects of evolocumab on low-density lipoprotein cholesterol, non-high density lipoprotein cholesterol, apolipoprotein\u00a0B, and lipoprotein(a) by race and ethnicity: a meta-analysis of individual participant data from double-blind and open-label extension studies. J Am Heart Assoc. 2021;10(1): e016839.","journal-title":"J Am Heart Assoc"},{"issue":"10","key":"304_CR22","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1002\/clc.23049","volume":"41","author":"E Stroes","year":"2018","unstructured":"Stroes E, Robinson JG, Raal FJ, et al. Consistent LDL-C response with evolocumab among patient subgroups in PROFICIO: a pooled analysis of 3146 patients from phase\u00a03 studies. Clin Cardiol. 2018;41(10):1328\u201335.","journal-title":"Clin Cardiol"},{"issue":"11","key":"304_CR23","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1253\/circj.CJ-20-1051","volume":"85","author":"AC Keech","year":"2021","unstructured":"Keech AC, Oyama K, Sever PS, et al. Efficacy and safety of long-term evolocumab use among asian subjects\u2014a subgroup analysis of the further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk (FOURIER) trial. Circ J. 2021;85(11):2063\u201370.","journal-title":"Circ J"},{"issue":"1","key":"304_CR24","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.jacl.2017.09.007","volume":"12","author":"KK Koh","year":"2018","unstructured":"Koh KK, Nam CW, Chao TH, et al. A randomized trial evaluating the efficacy and safety of alirocumab in South Korea and Taiwan (ODYSSEY KT). J Clin Lipidol. 2018;12(1):162.e6\u201372.e6.","journal-title":"J Clin Lipidol"}],"container-title":["Cardiology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-023-00304-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40119-023-00304-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-023-00304-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T10:44:21Z","timestamp":1684925061000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40119-023-00304-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,21]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["304"],"URL":"https:\/\/doi.org\/10.1007\/s40119-023-00304-x","relation":{},"ISSN":["2193-8261","2193-6544"],"issn-type":[{"value":"2193-8261","type":"print"},{"value":"2193-6544","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,21]]},"assertion":[{"value":"7 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}